Founded in 2001, Akubio Ltd. is one company seeking to tap the commercial potential of acoustic detection technology in drug discovery and development, as well as diagnostics. The company's Rupture Event Scanning (REVS) and Resonant Acoustic Profiling (RAP) platforms can be used to detect not only large molecules like viruses and bacterial cells, but also small molecule drugs, proteins or oligonucleotides. As well as being simpler, faster and cheaper than other detection technologies such as PCR and ELISA, Akubio's platforms can also generate information on the binding affinities and kinetics of molecules' interactions with their receptors.
You may also be interested in...
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.